601 related articles for article (PubMed ID: 30242397)
1. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
2. Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis.
Gordon LG; Tuffaha HW; James R; Keller AT; Lowe A; Scuffham PA; Gardiner RA
Urol Oncol; 2018 Mar; 36(3):91.e7-91.e15. PubMed ID: 29169847
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
4. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
5. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.
Aizer AA; Gu X; Chen MH; Choueiri TK; Martin NE; Efstathiou JA; Hyatt AS; Graham PL; Trinh QD; Hu JC; Nguyen PL
J Natl Compr Canc Netw; 2015 Jan; 13(1):61-8. PubMed ID: 25583770
[TBL] [Abstract][Full Text] [Related]
6. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
[TBL] [Abstract][Full Text] [Related]
7. The cost implications of prostate cancer screening in the Medicare population.
Ma X; Wang R; Long JB; Ross JS; Soulos PR; Yu JB; Makarov DV; Gold HT; Gross CP
Cancer; 2014 Jan; 120(1):96-102. PubMed ID: 24122801
[TBL] [Abstract][Full Text] [Related]
8. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of trends in the cost of initial cancer treatment.
Warren JL; Yabroff KR; Meekins A; Topor M; Lamont EB; Brown ML
J Natl Cancer Inst; 2008 Jun; 100(12):888-97. PubMed ID: 18544740
[TBL] [Abstract][Full Text] [Related]
11. Cost of care for elderly cancer patients in the United States.
Yabroff KR; Lamont EB; Mariotto A; Warren JL; Topor M; Meekins A; Brown ML
J Natl Cancer Inst; 2008 May; 100(9):630-41. PubMed ID: 18445825
[TBL] [Abstract][Full Text] [Related]
12. Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
Li TT; Shore ND; Mehra M; Todd MB; Saadi R; Leblay G; Aggarwal J; Griffiths RI
Cancer; 2017 Sep; 123(18):3591-3601. PubMed ID: 28542732
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
14. The burden of depression in prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
[TBL] [Abstract][Full Text] [Related]
15. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.
Dinan MA; Li Y; Zhang Y; Stewart SB; Curtis LH; George DJ; Reed SD
Clin Genitourin Cancer; 2016 Feb; 14(1):28-37.e2. PubMed ID: 26382223
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
Macleod LC; Yabes JG; Fam MM; Bandari J; Yu M; Maganty A; Furlan A; Filson CP; Davies BJ; Jacobs BL
Eur Urol Focus; 2020 Mar; 6(2):242-248. PubMed ID: 31031042
[TBL] [Abstract][Full Text] [Related]
17. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
18. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer.
Brown ML; Riley GF; Potosky AL; Etzioni RD
Med Care; 1999 Dec; 37(12):1249-59. PubMed ID: 10599606
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
20. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016.
Mukherjee K; Small W; Duszak R
Brachytherapy; 2022; 21(1):12-21. PubMed ID: 34380592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
